A Phase IB/IIA Multicenter, Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT02773030

Study #:
STUDY00143888

Start Date:
Oct 03, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02773030

View Complete Trial Details & Eligibility at ClinicalTrials.gov